NewsletterJohnson & Johnson-backed Rapport Therapeutics Developing a9a10 Agonist as Potential Tinnitus Treatment
NewsletterSage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus
NewsletterMetabolomic profiling for persistent tinnitus: a promising approach to identify tinnitus biomarkers and novel therapeutic targets
NewsletterHarvard Scientists Identify Metabolomic Biomarkers of Persistent Tinnitus that May Contribute to Discovery of Novel Therapeutic Targets
NewsOtonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
NewsletterFirst Look at 6B-001, 65Bio’s Preclinical Drug Candidate for the Treatment of Chronic Tinnitus
NewsAnti-Tinnitus Effects of “Prism Adaptation” Glasses: Researchers in France to Begin Major Study Next Month (August 2021)
NewsletterNew Research from Susan Shore Explores Connections Between Tinnitus, Hyperacusis, and Signal Processing in Noisy Environments
NewsKetamine + HD-tIPNS for tinnitus: Professor Dirk De Ridder investigates effects of new “drug/device combo” therapy
NewsResearchers evaluating the effects of bitter almond oil and cinnarizine on chronic tinnitus severity
